- Travere Therapeutics reported third quarter 2026 revenue of US$224.56 million and a net loss of US$52.34 million, compared with third quarter 2025 revenue of US$164.86 million and net income of US$25.71 million.
- The shift from profit to loss came alongside higher sales and reflected heavier operating and in-process R&D spending, which affected per share results despite revenue growth over both the quarter and the first nine months of 2026.
- This analysis examines how Travere Therapeutics’ investment narrative aligns with higher revenue and a much wider reported net loss.
See how Travere Therapeutics’ latest results compare with other healthcare stocks under earnings pressure by reviewing the hand picked list of solid balance sheet and fundamentals (24 results) in the sector.
Travere Therapeutics Investment Narrative Recap
To own Travere Therapeutics, you need to buy into a rare kidney and metabolic disease story where FILSPARI remains the commercial anchor and pegtibatinase and civorebrutinib build a broader portfolio over time. The analyst consensus Narrative on Simply Wall St leans on this multi asset setup. The recent quarter showed that high operating and in process R&D costs can quickly turn higher revenue into a sizeable loss.
The key short term swing factor is whether FILSPARI demand and reimbursement trends hold up, while expenses stay disciplined enough for losses to narrow. The biggest risk is that elevated R&D, SG&A and licensing charges like those seen in Q3 2026 persist, which would keep Travere Therapeutics reliant on external funding and delay any path to sustained profitability.
The earnings announcement for the third quarter of 2026 is the most relevant update. Travere Therapeutics reported US$224.56 million in quarterly revenue and a net loss of US$52.34 million, with nine month revenue of US$521.35 million and a net loss of US$124.24 million. These figures frame how much cash the commercial portfolio is generating relative to what is being reinvested.
For catalysts, that gap matters. The rare kidney thesis relies on FILSPARI plus future contributions from pegtibatinase and civorebrutinib to eventually cover large operating and R&D spend. Persistent quarterly losses and higher per share deficits highlight execution risk on costs and on delivering the HARMONY trial, the planned civorebrutinib program and any future label or uptake expansions on acceptable timelines.
Travere Therapeutics' current narrative ties to analyst expectations that revenue grows at about 33.3% a year, reaching US$1.5b of sales and US$507.9m of earnings by 2029. This implies an earnings swing of roughly US$662m from the current loss of US$154.4m reported in the assumptions.
Uncover why Travere Therapeutics' fair value indicates a 44% potential upside to its current price, a gap that could narrow quickly.
Exploring Other Perspectives
Not every analyst views Travere Therapeutics through the same lens. The most optimistic voices focus on earnings potential, not current losses, and were pencilling in about US$2.0b of revenue and US$1.1b of earnings by 2029 before this quarter and the upcoming conference talks. Treat those forecasts as one possible storyline, and explore several viewpoints before deciding how these fresh results might shift the narrative.
Explore 3 other Travere Therapeutics fair value estimates, including one that suggests as much as 367% upside from the current price.
The Verdict Is Yours
Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.
- A great starting point for your Travere Therapeutics research is our analysis highlighting 3 key rewards that could impact your investment decision.
- See our latest analysis for Travere Therapeutics. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Travere Therapeutics' overall financial health at a glance.
Looking for more investment ideas beyond Travere Therapeutics?
Once you have a view on Travere Therapeutics, it can help to widen the lens and compare it with other businesses that match different risk, income, and valuation profiles. The Simply Wall St Screener lets you filter for exactly the kind of stocks you want to research next.
- For investors who care most about balance sheet resilience and fundamentals, start with a curated list of solid balance sheet and fundamentals (24 results) that meet those quality filters.
- If you are hunting for mispriced opportunities, use the 32 high quality undervalued stocks to see which companies combine strong fundamentals with prices that look out of step with their metrics.
- Income focused readers can zero in on dependable cash payouts through a 6 dividend fortresses that currently offer yields of 5% or more.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com